Last $24.76 USD
Change Today +0.76 / 3.17%
Volume 402.6K
IPXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (IPXL) Snapshot

Open
$24.20
Previous Close
$24.00
Day High
$25.05
Day Low
$23.57
52 Week High
07/2/14 - $31.04
52 Week Low
10/15/13 - $19.39
Market Cap
1.8B
Average Volume 10 Days
462.1K
EPS TTM
$0.89
Shares Outstanding
70.7M
EX-Date
--
P/E TM
27.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPAX LABORATORIES INC (IPXL)

impax laboratories inc (IPXL) Related Businessweek News

No Related Businessweek News Found

impax laboratories inc (IPXL) Details

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The Global Pharmaceuticals Division develops, manufactures, sells, and distributes generic pharmaceutical products through its global products sales channel for sales of generic prescription products directly to wholesalers, retail drug chains, and others; private label product sales channel for generic over-the-counter (OTC) and prescription products to unrelated third-party customers; Rx partner sales channel for generic prescription products through unrelated third-party pharmaceutical entities; and OTC partner sales channel for OTC products through unrelated third-party pharmaceutical entities, as well as offers research and development services. The Impax Pharmaceutical Division develops proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia, as well as promotes third-party branded pharmaceutical products through its specialty sales force. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop and manufacture controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

973 Employees
Last Reported Date: 02/25/14
Founded in 1993

impax laboratories inc (IPXL) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $385.0K
President of Impax Pharmaceuticals Division
Total Annual Compensation: $500.5K
President of Global Pharmaceuticals Division
Total Annual Compensation: $486.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $470.2K
Compensation as of Fiscal Year 2013.

impax laboratories inc (IPXL) Key Developments

The Rosen Law Firm Announces Filing of Securities Class Action against Impax Laboratories Inc

The Rosen Law Firm announced that a class action lawsuit has been filed against Impax Laboratories Inc. on behalf of purchasers of Impax securities from May 20, 2013 through July 28, 2014. The lawsuit seeks to recover damages for Impax shareholders under the federal securities laws. Impax made material misrepresentations concerning: its failure to adhere to proper quality control and manufacturing practices at its Taiwan production facility; the potential material adverse effect of its quality control and manufacturing issues on its ability to launch its new drug, RYTARY; the quality control and manufacturing issues imperiling its ability to produce, sell, and distribute generic drugs; and the absence of a reasonable basis for the Defendants' positive statement concerning the company and its prospects. The lawsuit claims that when this adverse information entered the market, the price of Impax's securities dropped, damaging investors.

Impax Laboratories, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter Six Months Ended June 30, 2014; Provides Earnings Guidance for 2014

Impax Laboratories Inc. reported consolidated unaudited earnings results for the second quarter six months ended June 30, 2014. For the quarter, the company reported total revenues of $188,121,000 compared with $129,631,000 for the same period last year. Income from operations was $53,936,000 compared with $5,768,000 for the same period last year. Income before income taxes was $54,425,000 compared with $9,035,000 for the same period last year. Net income was $35,071,000 or $0.50 diluted per share compared with $5,619,000 or $0.08 diluted per share for the same period last year. Adjusted net income was $42,294,000 or $0.60 diluted per share compared with $15,918,000 or $0.23 diluted per share for the same period last year. Adjusted EBITDA was $76,222,000 compared with $36,240,000 for the same period last year. For the six months, the company reported was $306,839,000 compared with $278,120,000 for the same period last year. Income from operations was $62,167,000 compared with $10,039,000 for the same period last year. Income before income taxes was $63,055,000 compared with $162,755,000 for the same period last year. Net income was $41,496,000 or $0.59 diluted per share compared with $111,061,000 or $1.62 diluted per share for the same period last year. Net cash provided by operating activities was $12,420,000 compared with $169,144,000 for the same period last year. Purchases of property, plant and equipment was $18,271,000 compared with $20,075,000 for the same period last year. Adjusted net income was $58,775,000 or $0.84 diluted per share compared with $41,200,000 or $0.60 diluted per share for the same period last year. Adjusted EBITDA was $111,001,000 compared with $79,545,000 for the same period last year. The company full year 2014 estimates are based on management's current belief about prescription trends, pricing levels, inventory levels, and the anticipated timing of future product launches and events. The company updated its capital expenditures of approximately $40.0 million to $45.0 million. Effective tax rate of approximately 32% to 34% on a GAAP basis, which assumes that the U.S. R&D tax credit is renewed for 2014. The R&D tax credit expired on December 31, 2013. The company anticipates that its non-GAAP effective tax rate may experience volatility as the company's tax benefits may be high compared to the company's operating income or loss.

Impax Mulls Acquisitions

Impax Laboratories Inc. (NasdaqGS:IPXL) is looking for acquisitions. Fred Wilkinson, President And Chief Executive Officer Of Impax Laboratories said, "We remain excited about the business development and M&A landscape, which consists of a number of strategic prospects that fit our acquisition criteria".

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPXL:US $24.76 USD +0.76

IPXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPXL.
View Industry Companies
 

Industry Analysis

IPXL

Industry Average

Valuation IPXL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit www.impaxlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.